• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Baxter beats The Street with Q4 numbers, but Gambro buy pushes profits down

Baxter beats The Street with Q4 numbers, but Gambro buy pushes profits down

January 23, 2014 By Brad Perriello

Baxter beats The Street with Q4 numbers, but Gambro buy pushes profits down

Baxter (NYSE:BAX) beat Wall Street’s forecast for its 4th-quarter sales and earnings today, but a bottom-line hit from its $4 billion acquisition of Gambro and earnings guidance for 2014 combined to send its share price down a hair today.

Baxter posted profits of $326 million, or 59¢ per share, on sales of $4.37 billion for the 3 months ended Dec. 31, 2013, representing a 34.0% profit decline on 16.4% sales growth compared with the same period in 2012. Adjusted to exclude 1-time items, profits were $692.0 million, or $1.26 per share, a penny ahead of expectations on Wall Street. Baxter still managed to beat The Street’s top-line forecast by a cool $118 million.

Full-year profits came in at $2.01 billion, or $3.66 per share, on sales of $15.26 billion, for a 13.5% profit slide on 7.5% sales growth. Adjusted profits were $2.57 billion, for adjusted EPS of $4.67, again a penny ahead of The Street.

"We continue to meet our financial objectives while navigating a challenging and complex macro-environment," chairman & CEO Robert Parkinson Jr. said in prepared remarks. "We remain focused on the company’s strategic priorities of advancing the new product pipeline, investing in future growth opportunities, and strengthening our operational execution, which will result in enhanced value for patients, healthcare providers and shareholders."

Baxter said the buyout of Swedish dialysis giant Gambro was largely responsible for a $366 million, 67¢ after-tax charge during the 4th quarter.

First-quarter EPS are slated to reach $1.06 to $1.09 on sales growth of 13%-14%, according to a press release. Full-year EPS, pegged at $5.05 to $5.25 on sales growth 9%-10%, just meets expectations on The Street at the top end.

BAX shares were trading at $69.47 apiece as of about 1:40 p.m. today, down 0.4%.

Filed Under: MassDevice Earnings Roundup, Mergers & Acquisitions, News Well Tagged With: 2013, Baxter, Dialysis, Q4

More recent news

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Philips prices $1.1B offering to pay off debt, finance green projects
  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy